Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.
about
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancerCurrent Status of CTCs as Liquid Biopsy in Lung Cancer and Future DirectionsEGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published dataRecursive partitioning analysis of prognostic factors for patients with four or more intracranial metastases treated with radiosurgery.Downregulation of EGFR in a metastatic brain lesion of EGFR-mutated non-small cell lung cancer using a tyrosine kinase inhibitor: A case reportThe role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.Renal cell carcinoma and the use of sorafenib.A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancerBlood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy.EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumorsEffects of an Epithelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Add-on in Stereotactic Radiosurgery for Brain Metastases Originating from Non-Small-Cell Lung CancerTherapeutic resistance in lung cancer.Chemotherapy and targeted molecular therapies for brain metastases.Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases.Epigenetic Profiling of H3K4Me3 Reveals Herbal Medicine Jinfukang-Induced Epigenetic Alteration Is Involved in Anti-Lung Cancer Activity.High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cellsComparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastasesEfficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma.Icotinib as initial treatment in lung adenocarcinoma patients with brain metastasesGefitinib for asymptomatic brain metastasis from advanced non-small cell lung cancer: Report of a favourable outcome.Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients.Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports.Systemic treatment of non-small cell lung cancer brain metastasesA Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.Revisiting the role of molecular targeted therapies in patients with brain metastases.Gefitinib for non-small-cell lung cancer treatment.Management of brain metastasis: past lessons, modern management, and future considerations.EGFR mutation status in brain metastases of non-small cell lung carcinoma.EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.Molecular determinants of lung cancer metastasis to the central nervous system.Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.Erlotinib for the treatment of brain metastases in non-small cell lung cancer.Targeted Treatment of Brain Metastases.Napsin a and thyroid transcription factor-1-positive cerebellar tumor with epidermal growth factor receptor mutation.Evaluation on efficacy and safety of the addition of X-knife therapy to gefitinib in NSCLC patients with symptomatic brain metastases.
P2860
Q26740529-A5B26B95-18A4-414E-B873-5AD1BC2C76AFQ26781333-5CBFAB47-6E55-46B8-884B-8D1104EDC2FCQ30871237-2AD19183-AEC3-47FE-BE2D-05732C83CE0AQ33286060-4AD7BE02-5AAA-41BC-8860-6370D7E9B92EQ33597567-00A87969-3C6B-4EDB-BD98-08C49DB0F548Q33599167-F88E45BC-389E-4CBD-9496-E7ABCC1C7731Q34387448-48F19151-F8CF-4FE5-946E-C6F7F5D25C34Q34992513-FBC00FF7-9B4F-4E63-B289-018E32669883Q35166782-42525F6A-6EC2-44C6-B12A-DE1AE207BB62Q35552072-3C07AC6A-4A14-4241-A642-46976CCFA7A8Q35781600-3968A02F-09E0-42CE-9DA4-178AF9565BDEQ35800614-E3710239-4A7E-454C-B3C1-C1B0674D737BQ35914677-115B0BF1-8AF9-4E92-BCA9-9AD142A8D9D6Q36025680-340DF704-2C2C-42C8-8870-E81A1E770BFFQ36241305-E3DC3D81-1C5A-4CC6-BBE8-6D107462B50BQ36609767-D6F75389-E495-4748-842A-D2D27D6FA976Q36641504-84B771A8-E971-454D-AA0D-97FBE2A82EEAQ36682422-14C5BB8B-0DF4-4A59-A1AB-530645F1C836Q36759614-706B623E-FC53-4C85-A819-4F31883276ECQ36782286-D95F7760-B79C-4EFF-BB9A-2C2A5F8EF9B3Q36833970-48A3C9DB-D00B-4359-89FD-18535AEAB1CDQ36924484-27B7BC07-16F8-4DB9-AE7E-0E3E2243E933Q37060391-99907127-451C-4CAC-85AB-B4E40EE16556Q37060417-6E4E8126-8ACE-4B2E-980F-DE038EA37BDAQ37389605-476F2AD1-9053-4C50-B586-DC3A44047ACBQ37391069-20D3A2AC-6A1F-4044-87B6-7CFE7BFCE60FQ37646729-1F79B29C-0775-4ECE-867E-3FD82DDD733FQ37727648-C81F5A29-5A03-4726-9B11-BB871D96311EQ37742623-8984E9BF-8497-4A32-8F8B-931937F5EA03Q37904792-FEFB17D0-CEBE-42E8-A6A6-6C9D278BC30EQ37929795-2637ABC8-1C7A-4CC1-B6C1-A1D3FAC3D64BQ37954518-97E923AD-57C4-478F-BEAA-37BE8A1F04BBQ38053963-E604D982-F065-4BEA-8037-3725DF37E539Q38068204-0BE2987C-4EBD-4B7A-A9CB-5AFB70013A60Q38390049-5DE06C0C-14A0-4D4E-AC15-ADB99A2A98CAQ38763111-84F5224F-AE78-4B9F-B026-3420F9425B1AQ38770028-7EFFEE4F-7E67-4871-A0E6-0CCAFC32885AQ39192200-0B6BEA3C-5BA0-43C7-BC91-E63E1A994567Q40157407-AF6603DB-0E02-4B82-B284-56567B87D394Q41341233-26F16D8D-8504-4681-BC32-58D567F2F352
P2860
Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Gefitinib in patients with bra ...... : review of 15 clinical cases.
@ast
Gefitinib in patients with bra ...... : review of 15 clinical cases.
@en
type
label
Gefitinib in patients with bra ...... : review of 15 clinical cases.
@ast
Gefitinib in patients with bra ...... : review of 15 clinical cases.
@en
prefLabel
Gefitinib in patients with bra ...... : review of 15 clinical cases.
@ast
Gefitinib in patients with bra ...... : review of 15 clinical cases.
@en
P2093
P356
P1433
P1476
Gefitinib in patients with bra ...... : review of 15 clinical cases.
@en
P2093
Hajime Maeda
Hiromi Kimura
Manabu Niinaka
Masami Ito
Masaru Nakagawa
Satolo Kawamura
Soichiro Yokota
Takashi Kijima
Takeo Iwasaki
Tatsuya Okada
P304
P356
10.3816/CLC.2004.N.026
P407
P577
2004-09-01T00:00:00Z